Ultragenyx (RARE) reaffirmed its financial guidance for FY25. Revenues are expected to grow approximately 14%-20% compared to 2024. The company will continue to prioritize expense management, focusing its investments on the execution of multiple upcoming commercial launches and advancing multiple Phase 3 programs. Together, this is expected to lead to a reduction in 2025 net cash used in operations compared to 2024.
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RARE:
- Controversial doctor Vinay Prasad named CBER director, STAT reports
- RARE Upcoming Earnings Report: What to Expect?
- RBC sees Makary interview as potentially positive for biotech stocks
- Ultragenyx price target lowered to $80 from $83 at BofA
- Ultragenyx price target raised to $117 from $104 at JPMorgan